Editorial comment on: Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma.
Peter
P
Mulders
D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology*; D002292:Carcinoma, Renal Cell / Q000276:immunology / Q000517:prevention & control* / Q000556:secondary / Q000601:surgery; D003131:Combined Modality Therapy; D004195:Disease Models, Animal; D006801:Humans; D007680:Kidney Neoplasms / Q000276:immunology / Q000517:prevention & control* / Q000601:surgery; D008175:Lung Neoplasms / Q000556:secondary; D018655:Lymphocyte Count; D051379:Mice; D009392:Nephrectomy; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology / Q000473:pathology
D019496:Cancer Vaccines